NCT02880319 2025-09-09
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Emerald Clinical Inc.
Pfizer
Actuate Therapeutics Inc.